Navigation Links
Not All Heart Failure Drugs Boost Survival Equally
Date:1/11/2011

By Steven Reinberg
HealthDay Reporter

TUESDAY, Jan. 11 (HealthDay News) -- Over the course of five years, heart failure patients taking the blood pressure drug candesartan stood a higher chance of survival than those taking losartan did, Swedish researchers report.

In fact, 61 percent of those taking candesartan (Atacand) survived, compared with 44 percent of those taking losartan (Cozaar); this difference may be due to differences in the way the drugs work, the study authors noted.

"Heart failure is among our most common causes of death and hospitalization," said lead researcher Dr. Lars H. Lund, an associate professor in the department of cardiology at Karolinska University Hospital in Stockholm.

Both drugs belong to an important group of medications known as angiotensin II receptor blockers (ARBs) that decrease mortality and hospitalization in heart failure patients, he added. However, the efficacy of different drugs in this class appears to vary.

"Previously, it was believed that the particular type of angiotensin receptor blocker did not matter," Lund explained. "Here we show that candesartan is associated with less mortality than losartan in heart failure."

The report is published in the Jan. 12 issue of the Journal of the American Medical Association.

For the study, Lund's group collected data on 5,139 patients. Among these, 2,639 were treated with candesartan and 2,500 received losartan.

The researchers also found that one-year survival for those taking candesartan was 90 percent, while for those taking losartan it was 83 percent.

Based on these findings, Lund expects prescribing habits to change in favor of candesartan.

"Prescription of candesartan will probably increase and of losartan decrease. But this may be controversial, because candesartan is on patent and relatively expensive, whereas losartan is generic and much less expensive," he said.

For patients without prescription drug coverage, losartan has recently become available as a generic medication and costs $1 to $2 a day, according to Dr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles. Candesartan is a branded medication and costs $3 a day, he added.

Fonarow noted that "an ACE inhibitor is the first-line, guideline-recommended therapy for patients with heart failure. Losartan and candesartan are recommended for use in heart failure patients only if an ACE inhibitor is not well-tolerated. There are numerous generic options for ACE inhibitors, and these may cost as little as 10 cents a day."

Moreover, the comparative effectiveness of different angiotensin receptor blockers has not been studied extensively in patients with heart failure. However, trials with candesartan have been larger and more positive than studies conducted with losartan, Fonarow added.

More information

For more information on heart failure, visit the American Heart Association.

SOURCES: Lars H. Lund, M.D., Ph.D., associate professor, department of cardiology, Karolinska University Hospital, Stockholm, Sweden; Gregg Fonarow, M.D., American Heart Association spokesman and professor, cardiology, University of California, Los Angeles; Jan. 12, 2011, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Arm Artery No Better Than Leg Vein for Heart Bypass, Study Finds
2. Too Much TV May Be Linked to Heart Attack, Death Risk
3. Sugary Drinks, Foods Might Put Teens at Risk for Heart Disease
4. Spanish heart risk study challenges image of healthy Mediterranean diet and lifestyle
5. Gut Instinct May Stem From the Heart
6. Fish Oil May Help Some Heart Failure Patients
7. Smog Contributes to Dangerous Heart Rhythm Disorders
8. More Evidence Links Avastin to Heart Failure in Breast Cancer Patients
9. Higher Education May Benefit Some Heart Attack Patients
10. Roundup: 2010 Advances in Heart Disease and Stroke Care
11. Scientists Spot DNA Linked With Dangerous Heart Rhythms
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Not All Heart Failure Drugs Boost Survival Equally 
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: